… renal outcomes among the studies, we excluded inconsistent renal outcomes and retained
identical renal outcomes … We performed subgroup analyses on primary outcomes to verify if …

… , their individual components, and a standardised composite of renal outcomes including
worsening eGFR, end-stage renal disease, or renal death (see appendix for details). Safety …

… base that SGLT2 inhibitors in general are associated with favorable CV and kidney outcomes;
in addition, the present study refines understanding of important differences in outcomes …

… This meta-analysis sought to assess the efficacy of SGLT2 inhibitors on CV and renal
outcomes overall, and specifically in patients with eGFR under 60 mL/min/1.73 m 2 . …

… about the effects of SGLT2 inhibitors on hard kidney endpoints. The … kidney outcome trial
with an SGLT2 inhibitor and showed that, in patients with type 2 diabetes and chronic kidney …

… for future research targeting kidney outcomes with combination therapies as … kidney outcome
trials in patients with type 2 diabetes, the role of SGLT2i in non-diabetic proteinuric kidney …

… in renal function with one of four US approved SGLT2 inhibitors … Results: In patients with
T2DM and CKD, SGLT2 inhibitors are … after initiating therapy with SGLT2 inhibitors, but return to …

… an SGLT2 inhibitor compared with a placebo, has a renal protective effect in participants with
type 2 diabetes mellitus, chronic kidney disease … on Renal and Cardiovascular Outcomes in …

… We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2
inhibitors on major kidney outcomes in patients with type 2 diabetes and to determine the …

… between T2DM and CKD patients initiating SGLT2 inhibitors versus … SGLT2 inhibitors. We
also assessed whether the association between kidney outcomes and use of SGLT2 inhibitors …